The impact of curative cancer treatment on sexual health – clinical results from the EORTC QLQ-SH22 validation study

Anne S. Oberguggenberger,Veronika I. Engele,Claudia Schmalz,Andy Nordin,Vesna Bjelic-Radisic,Anne Lanceley,Karin Kuljanic,Pernille T. Jensen,Ligita Paskeviciute Frøding,Carien L. Creutzberg,Kristin Zimmermann,Samantha Serpentini,Juan I. Arraras,Eva Nagele,Hilde Toelen,Elfriede Greimel,on behalf of the EORTC Quality of Life Group,Dagmara Kulis,Chie Wie-Chu,Krzysztof A. Tomaszewski,Razvan Galalae,Thierry Almont
DOI: https://doi.org/10.1186/s12885-024-13123-7
IF: 4.638
2024-11-13
BMC Cancer
Abstract:The European Organization of Research and Treatment of Cancer (EORTC) has recently developed and validated a patient-reported outcome measure (PROM) for sexual health (SH) in cancer patients. Here, we present results from a secondary analysis of the EORTC QLQ-SH22 validation study. The objective was to investigate the impact of cancer treatment on SH over the disease trajectory into survivorship in patients who underwent curative treatment.
oncology
What problem does this paper attempt to address?